Excessive Collagen Turnover Products Are Released During Colorectal Cancer Progression and Elevated in Serum from Metastatic Colorectal Cancer Patients

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jul 29

PMID 27465284

Citations 56

Authors

S N Kehlet

R Sanz-Pamplona

S Brix

D J Leeming

M A Karsdal

V Moreno

Affiliations

Soon will be listed here.

Abstract

During cancer progression, the homeostasis of the extracellular matrix becomes imbalanced with an excessive collagen remodeling by matrix metalloproteinases. As a consequence, small protein fragments of degraded collagens are released into the circulation. We have investigated the potential of protein fragments of collagen type I, III and IV as novel biomarkers for colorectal cancer. Specific fragments of degraded type I, III and IV collagen (C1M, C3M, C4M) and type III collagen formation (Pro-C3) were assessed in serum from colorectal cancer patients, subjects with adenomas and matched healthy controls using well-characterized and validated ELISAs. Serum levels of the biomarkers were significantly elevated in colorectal cancer patients compared to subjects with adenomas (C1M, Pro-C3, C3M) and controls (C1M, Pro-C3). When patients were stratified according to their tumour stage, all four biomarkers were able to differentiate stage IV metastatic patients from all other stages. Combination of all markers with age and gender in a logistic regression model discriminated between metastatic and non-metastatic patients with an AUROC of 0.80. The data suggest that the levels of these collagen remodeling biomarkers may be a measure of tumour activity and invasiveness and may provide new clinical tools for monitoring of patients with advanced stage colorectal cancer.

Citing Articles

Clinical significances of liver fibrotic markers in patients with cholangiocarcinoma after radical resections.

Nanashima A, Hiyoshi M, Imamura N, Hamada T, Tsuchimochi Y, Wada T Turk J Surg. 2025; 40(4):283-295.

PMID: 39980645 PMC: 11832000. DOI: 10.47717/turkjsurg.2024.6486.

Multi-omics analysis of Prolyl 3-hydroxylase 1 as a prognostic biomarker for immune infiltration in ccRCC.

Ding G, Wang T, Sun F, Liu M, Tang G, Yu S NPJ Precis Oncol. 2024; 8(1):256.

PMID: 39516330 PMC: 11549470. DOI: 10.1038/s41698-024-00748-x.

Transcriptome Profiling Associated with Overexpression in Colorectal Cancer Implicates a Potential Role for Tumor Immune Microenvironment and Cancer Pathways Modulation via NF-κB.

Alhosani F, Ilce B, Alhamidi R, Manasa Bhamidimarri P, Hamad A, Alkhayyal N Int J Mol Sci. 2024; 25(19).

PMID: 39408697 PMC: 11476988. DOI: 10.3390/ijms251910367.

Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment.

Stewart D, Brisson B, Dekky B, Berger A, Yen W, Mauldin E NPJ Breast Cancer. 2024; 10(1):86.

PMID: 39358397 PMC: 11447064. DOI: 10.1038/s41523-024-00690-y.

COL6A3 Exosomes Promote Tumor Dissemination and Metastasis in Epithelial Ovarian Cancer.

Ho C, Yen T, Chang T, Huang S Int J Mol Sci. 2024; 25(15).

PMID: 39125689 PMC: 11311469. DOI: 10.3390/ijms25158121.

References

Gilkes D, Chaturvedi P, Bajpai S, Wong C, Wei H, Pitcairn S . RETRACTED: Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 2013; 73(11):3285-96. PMC: 3674184. DOI: 10.1158/0008-5472.CAN-12-3963. View

Walker A, Johnson E, Maykel J, Stojadinovic A, Nissan A, Brucher B . Future directions for the early detection of colorectal cancer recurrence. J Cancer. 2014; 5(4):272-80. PMC: 3982040. DOI: 10.7150/jca.8871. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Cox T, Erler J . Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res. 2014; 20(14):3637-43. DOI: 10.1158/1078-0432.CCR-13-1059. View

Xiong G, Deng L, Zhu J, Rychahou P, Xu R . Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 2014; 14:1. PMC: 3880410. DOI: 10.1186/1471-2407-14-1. View

Burt R . Colorectal cancer screening. Curr Opin Gastroenterol. 2010; 26(5):466-70. DOI: 10.1097/MOG.0b013e32833d1733. View

Veidal S, Karsdal M, Nawrocki A, Larsen M, Dai Y, Zheng Q . Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011; 4:22. PMC: 3204229. DOI: 10.1186/1755-1536-4-22. View

Duffy M, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R . Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007; 43(9):1348-60. DOI: 10.1016/j.ejca.2007.03.021. View

Hanna E, Quick J, Libutti S . The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2008; 15(1):8-17. DOI: 10.1111/j.1601-0825.2008.01471.x. View

10.

Cox T, Bird D, Baker A, Barker H, Ho M, Lang G . LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013; 73(6):1721-32. PMC: 3672851. DOI: 10.1158/0008-5472.CAN-12-2233. View

11.

Leeming D, Karsdal M, Byrjalsen I, Bendtsen F, Trebicka J, Nielsen M . Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther. 2013; 38(9):1086-96. PMC: 3935409. DOI: 10.1111/apt.12484. View

12.

Lu P, Weaver V, Werb Z . The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395-406. PMC: 3283993. DOI: 10.1083/jcb.201102147. View

13.

Willumsen N, Bager C, Leeming D, Smith V, Christiansen C, Karsdal M . Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 2014; 3(5):1136-45. PMC: 4302665. DOI: 10.1002/cam4.303. View

14.

Bonnans C, Chou J, Werb Z . Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014; 15(12):786-801. PMC: 4316204. DOI: 10.1038/nrm3904. View

15.

Leeman M, McKay J, Murray G . Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol. 2002; 55(10):758-62. PMC: 1769766. DOI: 10.1136/jcp.55.10.758. View

16.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

17.

Herszenyi L, Barabas L, Hritz I, Istvan G, Tulassay Z . Impact of proteolytic enzymes in colorectal cancer development and progression. World J Gastroenterol. 2014; 20(37):13246-57. PMC: 4188883. DOI: 10.3748/wjg.v20.i37.13246. View

18.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

19.

Naba A, Clauser K, Whittaker C, Carr S, Tanabe K, Hynes R . Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer. 2014; 14:518. PMC: 4223627. DOI: 10.1186/1471-2407-14-518. View

20.

Karsdal M, Manon-Jensen T, Genovese F, Kristensen J, Nielsen M, Sand J . Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015; 308(10):G807-30. PMC: 4437019. DOI: 10.1152/ajpgi.00447.2014. View